Alirocumab is a fully human monoclonal antibody to PCSK9. The ODYSSEY MONO study was the first alirocumab Phase III study to test a previously unused dose of 75 mg subcutaneously every 2 weeks in ...

JE: We are excited to rapidly progress towards initial results from our ongoing phase 3 program (ODYSSEY) with our investigational PCSK9-inihibitor alirocumab. "PCSK9 inhibition represents an ...

Alirocumab represents one of Sanofi's best drug prospects, after several setbacks in recent years. However, it is a crowded arena. Also following Amgen's evolocumab are Pfizer's bococizumab, Roche ...

2020;1a;2a;8b] Inclisiran (Leqvio, Novartis) is an siRNA that specifically targets the human PCSK9 mRNA. Inclisiran first received FDA approval in 2021. [Leqvio package insert;1a;6a] Alirocumab is ...

An expensive new drug, evolocumab (Repatha), developed by Amgen, significantly drops cholesterol levels and reduced the risk of major cardiovascular events, researchers reported in a study published ...

"If statins aren't a good fit, options like ezetimibe or PCSK9 inhibitors (like evolocumab or alirocumab) can be great ...

“The approved drugs, alirocumab and evolocumab, reduce LDL cholesterol by about 60% alone and up to 85% when combined with high-intensity statins and ezetimibe. PCSK9 inhibitors are generally ...